CCL24+monocytes drives resistance to anti-PD-L1 blockade in hepatocellular carcinoma

被引：0
|
作者：
Deng, Haijing
Sit, Grace Fu-Wan
Cheu, Jacinth Wing-Sum
Zhang, Yan
Liu, Cindy Xinqi
Chen, Yiling
Ooi, Zher Yee
Yuen, Vincent Wai-Hin
Ng, Irene Oi-Lin
Wong, Carmen Chak-Lui
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2024年 / 12卷 / 10期
关键词：
D O I：
10.1158/2326-6074.TUMIMM24-B018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B018
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The Curative Effect of Cryptotanshinone and anti-PD-L1 on Mouse Hepatocellular Carcinoma
    Han, Zhen
    Liu, Shuo
    Lin, Hongsheng
    Trivett, Anna
    Yang, De
    Oppenheim, Joost J.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [2] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [3] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [4] Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma
    Liang, Jiahua
    Ma, Mingjian
    Feng, Wei
    Xu, Qiongcong
    Chen, Dong
    Lai, Jiaming
    Chen, Jiancong
    APOPTOSIS, 2025, 30 (1-2) : 55 - 68
  • [5] Combination of anti-PD-L1 and radiotherapy in hepatocellular carcinoma: a mathematical model with uncertain parameters
    Shafiekhani, Sajad
    Gheibi, Nematollah
    Esfahani, Azam Janati
    SIMULATION-TRANSACTIONS OF THE SOCIETY FOR MODELING AND SIMULATION INTERNATIONAL, 2023, 99 (04): : 313 - 325
  • [6] Comparison of anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.
    Li, Shaohua
    Mei, Jie
    Wang, Qiaoxuan
    Zhao, Rongce
    Lu, Lianghe
    Deng, Min
    Lin, Wenping
    Guan, Renguo
    Wen, Yuhua
    Zheng, Lie
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 509 - 509
  • [7] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [8] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [9] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [10] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
12345